Fig. 1
Expression of tissue factor-specific procoagulant activity (TF PCA) by peripheral blood mononuclear cells (PBMCs) and markers of systemic coagulation activation. a PBMCs were isolated from patients with newly diagnosed acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), or myelodsyplastic syndrome (MDS) and analyzed for TF PCA, expressed as arbitrary units (AU), by single-stage clotting assay both before (intact) and after repeated freeze–thawing (disrupted). The dashed line indicates the upper limit of the reference range for TF PCA of intact PBMCs as determined by analysis of ten healthy controls. P values are according to Mann–Whitney U test. b Levels of PBMC-associated TF PCA according to FAB subtypes. P value is according to Kruskal–Wallis test. For illustration purposes only, data points with “zero” TF PCA were plotted as 1 AU/106 PBMCs in panels a and b. c In a subgroup of 20 patients, plasma levels of both D-dimer and thrombin–antithrombin (TAT) complexes were measured at initial presentation. Correlation coefficient and P value are according to the method of Spearman. d In two patients, D-dimer and TAT plasma levels were measured at presentation and during AML remission. e D-dimer plasma levels according to FAB subtypes. P value is according to Kruskal–Wallis test.